EVT:ETR
Evotec SE
€2.93
0.00%
(0.00) 1 دن
7 اکتوبر, 5:35:01 PM GMT +2 · EUR
search
تمام علامات
| علامت | قیمت | تبدیلی | % تبدیلی |
|---|
insights_autoEVT کے لیے سرفہرست بصیرتیں تخلیق کی جا رہی ہیں...
مارکیٹ کی سرمایہ کاری
52.49 کروڑ
اوسط والیوم
9.30 لاکھ
والیوم
1.19 ہزار
52 ہفتے میں اعلی
€7.30
52 ہفتے کا کم
€2.71
EPS
-€1.11
بقایہ شیئرز
17.79 کروڑ
ملازمین کی تعداد
4 ہزار
مارکیٹ کی سرمایہ کاری
52.49 کروڑ
اوسط والیوم
9.30 لاکھ
والیوم
1.19 ہزار
52 ہفتے میں اعلی
€7.30
52 ہفتے کا کم
€2.71
EPS
-€1.11
بقایہ شیئرز
17.79 کروڑ
ملازمین کی تعداد
4 ہزار
خبریں اور کہانیاں
ویب ذرائع اور خبروں کے پارٹنرز سے
AD HOC NEWS
·
18 گھنٹے پہلے
Evotec loses research chief. Evotec stock falls 2.03 percent
AD HOC NEWS
·
19 گھنٹے پہلے
Evotec stock falls 2.1 percent as Q2 revenue drops 16.21 percent
AD HOC NEWS
·
4 مہینے پہلے
Evotec stock after-hours at EUR 2.95: minus 0.67 percent versus prior close
پروفائل
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Evotec SE کے بارے میں